Targeted Protein Degradation
GPTKB entity
Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biological pathway
drug discovery strategy |
| gptkbp:advantage |
broader target space
catalytic mode of action overcomes limitations of traditional inhibitors potential for lower dosing |
| gptkbp:clinicalTrialPhase |
gptkb:NCT03888612
gptkb:NCT04072952 |
| gptkbp:enables |
removal of disease-causing proteins
targeting undruggable proteins |
| gptkbp:example |
gptkb:ARV-110
gptkb:ARV-471 gptkb:dBET1 CC-90009 |
| gptkbp:fieldOfStudy |
gptkb:pharmacy
chemical biology molecular biology |
| gptkbp:firstDescribed |
early 2000s
|
| gptkbp:hasApplication |
gptkb:cancer
therapeutics neurodegenerative disease treatment |
| gptkbp:hasPatent |
US patents on PROTACs
|
| https://www.w3.org/2000/01/rdf-schema#label |
Targeted Protein Degradation
|
| gptkbp:limitation |
drug resistance
delivery challenges off-target effects |
| gptkbp:mechanismOfAction |
ubiquitin-proteasome system
lysosomal degradation |
| gptkbp:publishedIn |
gptkb:Nature_Reviews_Drug_Discovery
gptkb:Annual_Review_of_Pharmacology_and_Toxicology gptkb:Cell_Chemical_Biology |
| gptkbp:relatedTo |
small molecule drugs
targeted therapy E3 ubiquitin ligase protein homeostasis |
| gptkbp:studiedBy |
academic institutions
pharmaceutical companies |
| gptkbp:technology |
gptkb:AUTACs
gptkb:LYTACs Degronimids PROTACs molecular glues |
| gptkbp:bfsParent |
gptkb:Kymera_Therapeutics
|
| gptkbp:bfsLayer |
7
|